HMO1 Antibody

What is HMO1 and how does it relate to other HMGB proteins?

HMO1 belongs to the high-mobility group box (HMGB) protein family, which is highly conserved across eukaryotes. In Saccharomyces cerevisiae (budding yeast), HMO1 is an abundant HMGB protein that binds to ribosomal RNA gene coding regions and approximately 70% of ribosomal protein gene promoters. HMO1 shares functional similarity with human UBF1 and Schizosaccharomyces pombe Sp-HMO1, indicating evolutionary conservation of these nucleolar HMGB proteins involved in rDNA transcription. When expressed in human cells, yeast HMO1 co-localizes with UBF in nucleoli and concentrates on NORs (Nucleolar Organizer Regions) on metaphase chromosomes, demonstrating functional conservation across species .

What is the domain organization of HMO1?

HMO1 is organized into four functional domains:

• A dimerization module at the N-terminus

• A canonical HMGB motif

• A conserved domain

• A C-terminal nucleolar localization signal

The C-terminal domain (CTD) is dispensable for some functions of HMO1, while the other motifs are strictly required for RNA polymerase I stimulation. Interestingly, ribosomal protein gene stimulation requires neither the dimerization motif nor the conserved domain, suggesting functional specialization of different domains .

How do HMO1 and HMGB1 function in cellular processes?

HMO1 in yeast plays multiple roles in genome maintenance and transcriptional regulation:

• Binds to ribosomal RNA gene coding regions and ribosomal protein gene promoters

• Interacts with TFIID and localizes at RNA Polymerase II transcription start sites

• Suppresses chromosome fragility during S phase (along with Top2)

• Participates in DNA damage tolerance pathways

• Modulates both recycling of parental histones and deposition of new histones at replication forks

HMGB1 in mammals functions both intracellularly and extracellularly:

• Inside cells: Acts as a DNA chaperone and architectural protein

• Outside cells: Functions as an inflammatory mediator that promotes monocyte migration and cytokine secretion

• Mediates T cell-dendritic cell interaction

• Is released during cell death or actively secreted as an acetylated form via secretory endolysosome exocytosis

• Signals through RAGE (Receptor for Advanced Glycation End-products) and possibly TLR2/TLR4

What are the validated applications for HMO1/HMGB1 antibodies?

Based on the search results, validated applications for HMGB1 antibodies include:

The search results specifically mention that optimal dilutions should be determined by each laboratory for each application .

How can I detect HMO1/HMGB1 in different experimental systems?

For Western blot detection of human and mouse HMGB1:

• Prepare lysates from cell lines (e.g., HeLa) or tissues (e.g., mouse lactating tissues)

• Separate proteins using SDS-PAGE and transfer to PVDF membrane

• Block membrane using appropriate blocking buffer

• Probe with 1 μg/mL of anti-HMGB1 antibody

• Detect using HRP-conjugated secondary antibody

• A specific band should be visible at approximately 25 kDa

• Conduct under reducing conditions using appropriate immunoblot buffer

For immunofluorescence detection in human cells:

• Fix and permeabilize cells according to standard protocols

• Incubate with anti-HMGB1 antibody at appropriate dilution

• Use fluorophore-conjugated secondary antibody for detection

• Expect nucleolar localization with low nucleoplasmic signal in interphase cells

• On metaphase chromosomes, expect concentration at NORs

What controls should I include when using HMO1 antibodies?

When using HMO1/HMGB1 antibodies, include:

• Positive controls:

  • HeLa cell lysates for human HMGB1

  • Mouse lactating tissue lysates for mouse HMGB1

  • Cells with known high expression of HMGB1

• Negative controls:

  • Secondary antibody only (omit primary antibody)

  • Non-immune IgG from the same species as the primary antibody

  • When possible, HMGB1 knockout or knockdown samples

• Specificity controls:

  • Pre-adsorption with recombinant HMGB1 protein

  • Blocking peptide competition assay

How can synthetic antibodies against HMGB1 be developed and utilized?

Synthetic antibodies (SAs) against HMGB1 can be developed using copolymer nanoparticle technology:

• Library synthesis approach:

  • Create a library of lightly cross-linked N-isopropylacrylamide (NIPAm) hydrogel copolymers

  • Include functional monomers like trisulfated 3,4,6S-GlcNAc and hydrophobic N-tert-butylacrylamide

  • Screen for nanomolar affinity binding to HMGB1

  • Select candidates that bind the target protein domain (e.g., heparin-binding domain)

• Validation methods:

  • Competition binding experiments with heparin to determine binding domain

  • In vitro functional assays (e.g., inhibition of HMGB1-dependent ICAM-1 expression)

  • Assessment of ERK phosphorylation inhibition

  • Blood-brain barrier penetration studies using labeled SAs

• Applications:

  • Treatment of ischemic conditions like cerebral ischemia/reperfusion injury

  • Blocking HMGB1-RAGE interactions in inflammatory diseases

  • Targeting HMGB1 functions in specific tissues via biomarker-directed delivery

What is the role of HMO1 in DNA damage tolerance and repair?

HMO1 participates in DNA damage tolerance (DDT) through multiple mechanisms:

• Directing DNA lesions to template switching (TS) pathway:

  • HMO1 functions upstream of Rad5 and Mph1 to channel DNA lesions to the TS pathway

  • Deletion of HMO1 (hmo1Δ) suppresses MMS-sensitivity of rad5Δ and mph1Δ mutants

  • HMO1 aids in the formation of sister chromatid junctions (SCJs) that are processed by TS

• Regulation of histone dynamics:

  • HMO1 modulates both recycling of parental histones and deposition of new histones at replication forks

  • HMO1 antagonizes histone H2A variant H2A.Z (Htz1 in yeast) in DDT

  • The hmo1-AB mutant (lacking C-terminal domain) suppresses MMS sensitivity of htz1Δ and swr1Δ mutants

• Processing of DDT intermediates:

  • HMO1 may direct template switching intermediates (SCJs) to Mus81/Mms4-mediated resolution rather than STR-mediated dissolution

  • HMO1 is required for DNA damage checkpoint signaling induced by MMS

How do HMO1 domains contribute to its different cellular functions?

The functional domains of HMO1 contribute differently to its cellular roles:

• C-terminal domain (CTD):

  • Dispensable for certain functions (deletion does not affect all activities)

  • Not required for HMO1's function in suppressing MMS sensitivity in htz1Δ or swr1Δ mutants

  • Essential for HMO1's functions in cells lacking Rad5, Rtt107, Slx4, Srs2, or Cac2

• Dimerization module and HMGB motif:

  • Strictly required for RNA Polymerase I stimulation

  • Dimerization module is not required for ribosomal protein gene stimulation

• Conserved domain:

  • Required for Pol I stimulation

  • Not required for ribosomal protein gene stimulation

These domain-specific functions demonstrate that HMO1 has acquired species-specific functions while sharing ancestral functions with UBF1 and Sp-HMO1 in stimulating rDNA transcription .

How can I resolve inconsistent results when using HMO1 antibodies in different experimental contexts?

Inconsistent results with HMO1 antibodies may arise from several factors:

• Antibody specificity considerations:

  • Human HMGB1 is 100% amino acid identical to canine HMGB1

  • Human HMGB1 is 99% amino acid identical to mouse, rat, bovine, and porcine HMGB1

  • Cross-reactivity between species should be considered when interpreting results

  • Confirm antibody specificity for your species of interest

• Post-translational modifications:

  • HMGB1 undergoes acetylation during secretion

  • Different forms (nuclear vs. extracellular) may have different epitope accessibility

  • Consider using antibodies specific for modified or unmodified forms depending on your research question

• Experimental conditions:

  • Optimize antibody dilutions for each application and cell type

  • Use appropriate buffer conditions (the search results mention using Immunoblot Buffer Group 8 for Western blot)

  • Consider reducing vs. non-reducing conditions based on epitope accessibility

• Genetic background effects:

  • Different yeast strains may show variable phenotypes with HMO1 mutations

  • For example, different reports show varying results for C-terminal deletions of HMO1 (compare hmo1-AB vs. hmo1-Δ64 or hmo1-Δ22)

What approaches can resolve contradictions in HMO1 function studies across different model systems?

To address contradictions in HMO1 function studies:

• Cross-species comparative analysis:

  • Express HMO1 in heterologous systems (e.g., yeast HMO1 in human cells)

  • Compare localization patterns and functional rescue capabilities

  • For example, yeast HMO1 co-localizes with UBF in nucleoli when expressed in human cells

• Domain swapping experiments:

  • Create chimeric proteins combining domains from different species

  • Test functional complementation in various genetic backgrounds

  • This approach has revealed both conserved and species-specific functions

• Genetic interaction profiling:

  • Test hmo1 mutations in combination with mutations in related pathways

  • Analyze suppression or enhancement of phenotypes

  • Example: hmo1Δ suppresses MMS sensitivity of rad5Δ, mph1Δ, and other DNA repair mutants

• Alternative experimental approaches:

  • Compare results using both genetic (knockout/mutation) and biochemical (antibody inhibition) methods

  • Use synthetic antibodies or other binding reagents as alternative tools

  • Employ different functional assays to measure the same biological process

What methodological considerations are important when designing experiments with HMO1 antibodies?

Critical methodological considerations include:

• Antibody selection:

  • Choose antibodies validated for your specific application

  • Consider epitope location relative to functional domains

  • Determine if you need antibodies that recognize specific post-translational modifications

• Experimental design factors:

  • Include appropriate positive and negative controls

  • Consider timing of sample collection (HMGB1 localization and modification state changes upon stimulation)

  • Account for technical variations with biological replicates

• Data interpretation:

  • Be aware that HMO1/HMGB1 functions are context-dependent

  • Different domains contribute differently to various cellular processes

  • C-terminal truncation experiments have yielded inconsistent results across studies

• Complementary approaches:

  • Combine antibody-based detection with genetic approaches

  • Consider using synthetic antibodies for specific inhibition studies

  • Validate key findings using multiple methodologies

How might HMO1 antibodies contribute to studying DNA damage response mechanisms?

HMO1 antibodies can facilitate several approaches to studying DNA damage response:

• Chromatin immunoprecipitation (ChIP) studies:

  • Track HMO1 recruitment to damaged DNA sites

  • Identify binding patterns at replication forks

  • Examine co-localization with DNA repair factors after damage

• Live-cell imaging applications:

  • Use fluorescently tagged antibody fragments to track HMO1 dynamics during DNA damage

  • Examine localization changes following genotoxic stress

  • Study interactions with other repair factors in real time

• Mechanistic investigations:

  • Use antibodies to block specific HMO1 domains to dissect their roles in repair

  • Probe interactions with histone variants (e.g., H2A.Z) at damage sites

  • Examine role in template switching pathway regulation

What is the potential for developing therapeutic approaches targeting HMGB1 in inflammatory conditions?

Therapeutic approaches targeting HMGB1 show promise for inflammatory conditions:

• Synthetic antibody technology:

  • Copolymer nanoparticles can be designed with nanomolar affinity for HMGB1

  • These can target specific domains (e.g., heparin-binding domain on Box A)

  • Such synthetic antibodies can inhibit HMGB1-RAGE interaction

• Applications in cerebral ischemia/reperfusion injury:

  • Anti-HMGB1 synthetic antibodies cross the blood-brain barrier in injury models

  • Administration dramatically reduces brain damage in temporary middle cerebral artery occlusion model rats

  • They accumulate in ischemic brain regions following reperfusion

• Advantages over traditional antibodies:

  • Potentially lower immunogenicity

  • More consistent production

  • Tailorable binding properties

  • Potentially better tissue penetration

  • Modifiable pharmacokinetic properties

How do HMO1-histone interactions influence chromatin dynamics during DNA replication and repair?

HMO1-histone interactions play significant roles in chromatin dynamics:

• Regulation of histone deposition:

  • HMO1 modulates both recycling of parental histones and deposition of new histones at replication forks

  • This function is important for DNA damage tolerance pathways

• Antagonism with histone variant H2A.Z:

  • HMO1 antagonizes histone H2A.Z (Htz1 in yeast) in DNA damage tolerance

  • The C-terminal domain of HMO1 is dispensable for this function, as hmo1-AB mutant suppresses MMS sensitivity of htz1Δ and swr1Δ mutants

• Potential mechanisms:

  • HMO1 may compete with H2A.Z for nucleosome binding

  • HMO1 might influence SWR1 complex activity (which deposits H2A.Z)

  • HMO1 could affect chromatin compaction at replication forks

  • These interactions may influence accessibility of DNA to repair factors